FibroGen (NASDAQ:FGEN) Coverage Initiated by Analysts at StockNews.com

by · The Cerbat Gem

StockNews.com assumed coverage on shares of FibroGen (NASDAQ:FGEN – Free Report) in a research note issued to investors on Saturday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of FibroGen in a report on Tuesday, March 18th.

Read Our Latest Research Report on FGEN

FibroGen Stock Performance

NASDAQ:FGEN opened at $0.37 on Friday. The stock has a market cap of $37.24 million, a price-to-earnings ratio of -0.30 and a beta of 0.82. FibroGen has a 1 year low of $0.18 and a 1 year high of $2.80. The business has a fifty day moving average of $0.48 and a 200-day moving average of $0.43.

FibroGen (NASDAQ:FGEN – Get Free Report) last posted its quarterly earnings data on Monday, March 17th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). The company had revenue of $3.14 million during the quarter, compared to analyst estimates of $24.91 million. On average, equities research analysts predict that FibroGen will post -0.8 EPS for the current year.

Insider Activity

In other FibroGen news, Director James A. Schoeneck bought 250,000 shares of the company’s stock in a transaction that occurred on Thursday, March 20th. The shares were acquired at an average cost of $0.35 per share, for a total transaction of $87,500.00. Following the acquisition, the director now directly owns 323,722 shares of the company’s stock, valued at $113,302.70. This trade represents a 339.11 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Insiders own 1.98% of the company’s stock.

Institutional Trading of FibroGen

Large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its holdings in shares of FibroGen by 3.1% in the third quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock valued at $433,000 after buying an additional 32,884 shares in the last quarter. Two Sigma Securities LLC acquired a new position in shares of FibroGen in the 4th quarter worth $27,000. FMR LLC raised its position in shares of FibroGen by 21.8% during the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock worth $153,000 after purchasing an additional 68,569 shares during the period. XTX Topco Ltd lifted its holdings in shares of FibroGen by 423.8% during the fourth quarter. XTX Topco Ltd now owns 96,025 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 77,693 shares during the last quarter. Finally, Velan Capital Investment Management LP purchased a new stake in shares of FibroGen during the fourth quarter valued at $42,000. 72.71% of the stock is currently owned by institutional investors.

About FibroGen

(Get Free Report)

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.

Read More